Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Lambert Eaton Myasthenic Syndrome (LEMS) Clinical Trial

Official title: Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes With 3, 4-Diaminopyridine

Status No longer available

Clinical Trial Summary

Lambert Eaton Myasthenic Syndrome (LEMS) is rare neurological disorder that results in muscle weakness and limited reflex activity. More than half of LEMS cases are associated with a malignancy, usually small cell lung cancer, and tend to progress more quickly than cases not coupled with malignant cells.

3,4diaminopyridine (3,4DAP)is a drug that has been demonstrated to be effective in treating the weakness associated with LEMS as it increases strength and improves autonomic symptoms in LEMS patients. It is not currently approved by the FDA for use in the United States. The investigators plan to use 3,4DAP to treat patients with LEMS here at the Columbia University MDA/ALS Research Center.

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

• Lambert Eaton Myasthenic Syndrome (LEMS)
• Lambert-Eaton Myasthenic Syndrome
• Myasthenic Syndromes, Congenital
• Syndrome

• NCT number: NCT01378546
• Study type: Expanded Access
• Source: Columbia University
• Status: No longer available
• Phase: N/A
• Start date: May 2005